
Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized

Redeye updates its view of Nanexa following the Q4 report and recent events in the company. The report offered no surprises and we reiterate our stance that 2024 will be an important year for the company, as we hope for a breakthrough related to its partner deals and NEX-22 clinical trial.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized](#)